References
- Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555–62.
- Datta AR, Jiang YZ, Guimaraes A et al. Distinct T-cell populations distinguish chronic myeloid leukemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant 1994;14:517–24.
- Mavroudis DA, Jiang YZ, Hensel N et al. Specific depletion of alloreactivity against haplotype mismatched related individuals by recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant 1996;17: 793–9.
- Mavroudis DA, Dermime S, MolldremJJ et al. Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-vs-host and graft-vs-leukaemia reactions. Br J Haematol 1998;101:565–70.
- Jiang YZ, Mavroudis DA, Dermime S et aL Preferential usage ofT cell receptor (TCR) Vbeta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating GVL from G VH D. Bone Marrow Transplant 1997;19:899–903.
- Koh MB, Prentice HG, Corbo M et al. Alloantigen-specific T-cell depletion in a major histocompatibility complex fully mismatched murine model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment. Br J Haematol 2002;118:108–16.
- Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 2002;99:3083–8.
- Solomon SR, Tran T, Carter CS et al. Optimized clinical scaleculture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GVHD prophylaxis in allogeneic peripheral blood stem cell transplantation. Cytotherapy2002;4:395–406.
- Hensel N, Agarwala V, Jiang YZ et al. A Technique for dual detection of cytotoxic and helper lymphocyte precursor fre-quency by a miniaturized dye-release method. Bone Marrow Transplant 1999;23:71–8.
- Espinoza-Delgado IJ, Shetty V, Geller N et al. Impact of age on transplant related mortality following fludarabine and cyclophosphamide-based nonmyeloablative allogeneic hemato-poietic cell transplantation. Blood 2003;102(Suppl 1):265a.
- Gastineau DA. Will regulation be the death of cell therapy in theUnited States? Bone Marrow Transplant 2004;33:777–80.